Abstract:Abstract Background Inflammatory bowel diseases encompass two pathologies affecting the digestive tract, Crohn’s disease (CD) and ulcerative colitis (UC). They are characterized by a high and chronic inflammatory rate, resulting from activation of the intestinal immune system and increased permeability of the intestinal barrier leading to lesions in the intestinal tract. Non-classical CD14- CD16+ monocytes, are recruited to the focus of inflammation from the peripheral blood and preferentially differentiate to anti-inflammatory macrophages CD206+ CD163+ HLA-DR- in the intestine, playing a key role in the repair of such lesions. In some cases, treatment with biologics, such as vedolizumab, could interfere with this biological process leading to a modification of the innate immune response. Previous results showed that CD and UC had a different distribution of non-classicalmonocytes, leading to the hypothesis that treatment with biologic could modulate macrophage wound healing response. Methods Macrophages derived by THP-1 cells were polarized to M0, after PMA treatment, followed by LPS and IFN-γ for M1 macrophages, or IL-4 and IL-13 for M2 macrophages. To assess the effect of biologics on macrophage immune response, Infliximab (IFX) and Vedolizumab (VDZ) were added independently to the cell cultures until polarization process finalized. Immunophenotyping of M0, M1 and M2, and transcription factor expression profiling of pSTAT-1, pSTAT-6 and pNFκB, were carried out by flow cytometry. Cytokine production of IL-6, TGF-β and IL-10, was performed by ELISA immunoblot. Macrophages immune response was assessed with wound healing assay with Caco-2. Results Immunophenotyping revealed that M1 macrophages increased the expression of surface markers like HLA-DR, CD38 and reduced CD11c, vs. M0 macrophages, indeed transcription factor expression of pSTAT-6 and pNFκB were modulated. M2 macrophages showed the decrease of CD163 and HLA-DR vs. M0 macrophages, while no significant effect was observed for CD38 and CD206. Transcription factor expression revealed that pSTAT 6 incremented vs. M0. Cytokine profiling showed a clear difference between the tree macrophages types. Finally wound healing assay with Caco-2 revealed how biologic interfered with innate immune response. Conclusion Our results demonstrated that the treatment administration could be responsible of macrophage differential immune response, especially upon biologic treatment. These findings could lead to support the establishment of precision medicine in order to modulate a suitable macrophage response.

Expression of the Tim3‐galectin‐9 axis is altered in drug‐induced maculopapular exanthema

Anti-TNF- Αtreatment-Related Pathways and Biomarkers Revealed by Transcriptome Analysis in Chinese Psoriasis Patients

Galectin-9 contributes to the pathogenesis of atopic dermatitis via T cell immunoglobulin mucin-3

Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

The abnormal expression of Tim-3 is involved in the regulation of myeloid-derived suppressor cells and its correlation with preeclampsia

TIM-3 as a new therapeutic target in systemic lupus erythematosus

Response to extracorporeal photopheresis therapy of patients with steroid-refractory/-resistant GvHD is associated with up-regulation of Th22 cells and Tfh cells

Phenotypical analysis of ectoenzymes CD39/CD73 and adenosine receptor 2A in CD4 + CD25 high Foxp3 + regulatory T-cells in psoriasis.

Dysregulated Tim-3 expression and its correlation with imbalanced CD4 helper T cell function in ulcerative colitis.

Expression of Gal-9 on Dendritic Cells and Soluble Forms of TIM-3/Gal-9 in Patients Suffering from Endometriosis

Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy

Tim-3: An Activation Marker and Activation Limiter of Innate Immune Cells

Upregulation of the Tim-3/Gal-9 pathway and correlation with the development of preeclampsia

Differential effects of galectin-9 ligation with TIM-3 expressed on Th1 and Tregs (89.12)

Towards therapeutic drug monitoring of mycophenolic acid in mucous membrane pemphigoid: A retrospective single-centre study

TIM-3 regulates the NETs-mediated dendritic cell activation in myeloperoxidase-ANCA-associated vasculitis

Differential Upregulation of Th1/Th17-Associated Proteins and PD-L1 in Granulomatous Mycosis Fungoides

P047 Effect of infliximab and vedolizumab on M1 and M2 macrophages derived from THP-1 cells

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

TIM3/CEACAM1 pathway involves in myeloid-derived suppressor cells induced CD8+ T cells exhaustion and bone marrow inflammatory microenvironment in myelodysplastic syndrome